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was also administered by telephone to a representative commu-
nity sample more than 15 years old, selected by the quota
method. The prevalence of FM was estimated in the general
population, multiplying the percentage of conﬁrmed cases among
positive screens, i.e. the predictive positive value, observed in
consultation, to the positive screens in the general population.
RESULTS: A total of 56.7 % patients interviewed in the
rheumatology department were screened positive for chronic
widespread pain, 38% for widespread pain and fatigue, 20.3%
[19.8–20.8] were conﬁrmed FM cases. In the general adult popu-
lation, 12.8% were screened positive for widespread pain and
9.8% widespread pain and fatigue. The prevalence in general
population, is 3.7 % [2.0–5.4], if patients screened positive for
chronic widespread pain are considered. If fatigue is added, the
prevalence of 3.6 % [2.0–5.2]. Prevalence rises with age until the
age group 65–74 years old. FM sufferers are 97,7% females and
an average age of 59.2 years old (SD: 12). CONCLUSIONS: Our
study conﬁrms the results of publications in Canada, US or
Spain, with slightly differences probably due to the different
methodologies and populations used. The minimum prevalence
estimated of 3.6% in Portugal corresponds to 300 thousand of
FM sufferers.
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OBJECTIVES: To assess the estimated prevalence of possible
ﬁbromyalgia (FM) sufferers in Spain among the adult population
using a screening questionnaire, the London Fibromyalgia
Epidemiology Study—Screening Questionnaire (LFESSQ).
METHODS: Every patients going to visit a rheumatologist in
hospital in Cádiz and Barcelona during a 30-days period, were
interviewed using the LFESSQ with two additional questions on
fatigue, validated in spanish, and examined to conﬁrm or exclude
the diagnostic of FM using American College of Rheumatology
(ACR) classiﬁcation criteria. The screening questionnaire was
also administered to a representative community sample more
than 15 years old, selected by the quota method. The prevalence
of FM was estimated in the general population, applying the
predictive positive value, observed in consultation, to the positive
screens. RESULTS: In rheumatology outpatients, 45.2% patients
were screened positive for chronic widespread pain, 25.5% for
widespread pain and fatigue, 7.9% [5.5–8.2] were conﬁrmed FM
cases. In the general adult population, 22.5% were screened
positive for widespread pain and 9.5% widespread pain and
fatigue. The prevalence in general population, is 4.0% [2.8–5.2],
if patients screened positive for chronic widespread pain are
considered. If fatigue is added, the prevalence of 2.3% [1.4–3.2].
Prevalence rises with age until the age group 75–84 years old. FM
sufferers are 94.7% females and an average age of 53.9 years old.
CONCLUSIONS: Related to the general spanish population, one
can estimate the prevalence at 2%, and 3.2% among the women
and 0.58% among men, what conﬁrms previous reports and
publications.
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OBJECTIVES: To assess in Russia the estimated prevalence of
ﬁbromyalgia syndrome (FM) among the adult population in the
general population, using the London Fibromyalgia Epidemiol-
ogy Study—Screening Questionnaire (LFESSQ) and American
College of Rheumatology (ACR) classiﬁcation criteria.
METHODS: The validated Russian version of the LFESSQ was
administered to a representative community sample of 1610
subjects aged over 15 years, selected by the quota method. A
positive screen was deﬁned as meeting the 4-pain criteria alone
(LFESSQ-4), or meeting both the 4-pain and 2-fatigue criteria
(LFESSQ-6). The positive predictive value of LFESSQ-4 and
LFESSQ-6, was estimated in different European countries, this
questionnaire was submitted to a sample of rheumatology out-
patients (n = 1125), who were then examined by a trained rheu-
matologist to conﬁrm or exclude the diagnosis of FM according
to the 1990 American College of Rheumatology criteria. The
prevalence of FM in the Russian general population was esti-
mated by applying the predictive positive value to eligible com-
munity subjects in Russia. RESULTS: The community sample is
constituted of 885 females and 725 men. 20.1% screened posi-
tive for LFESSQ-4 (25.3% in females and 13.7% in males respec-
tively). A total of 13.8% screened positive for LFESSQ-6 (18.4%
in females and 8.1% in males respectively). Based on positive
screens for LFESSQ-4, the prevalence of FM would be estimated
at 7.1% (95% CI: 3.7–10.5; 8.9% in females and 4.8% in males
respectively) in the Russian general population. The correspond-
ing ﬁgure was 5.9% (95% CI: 2.8–9.0; 7.8% in females and
3.5% in males respectively) if positive screens for LFESSQ-6
were considered. CONCLUSIONS: These results are slightly
higher than those described in Canada, US or Spain, probably
due to the different methodologies and populations used. A point
prevalence of 5.9% would translate in approximately 6.9 million
of patients with FM in Russia.
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OBJECTIVES: The aim of this retrospective study is the evalua-
tion of relationship between one year mortality following the
treatment of femoral neck fracture and the usual risk factors
1) without differentiating, and 2) with differentiating the
co-morbidities.METHODS:Datawere derived from the database
of the National Health Insurance Fund Administration. The study
includes patients over 60 years following primary treatment of
femoral neck fracture (S7200) discharged from inpatient care
institutions in 2000. The patients with polytrauma were excluded
from the study. Data were evaluated according to sex, type of
fracture (Garden 3-4, Garden 1-2, lateral), patient turnover of
institutions, type of surgery (osteosynthesis/arthroplasty), early
complications, hospital type (university, capital, county, city), day
of operation (week day, week-end), surgical delay (over 24h,
12–24h, 6–12h, 0–6h), different co-morbidities according to ICD
codes (C00-C97, D60-D64, E10-E16, F00-F99, G20-G26, G80-
G83, I10-I15, I20-I25, I30-I52, I60-I69, I70, J00-J22, J40-J47,
L89,N30-N39). Statistical analysis has been performed by logistic
regression (OR(95%CI)p < 0,05) RESULTS: Altogether 3783
patients were involved into the study. We found the following
signiﬁcant predictors (odds ratios and p values are listed):
(I) without differentiating co-morbidities. Age (70–79/60–
69y):1.973(0.002), (80–89/60–69y):2.6959(0), (90–/60–
69y):5.8126(0), Sex (female/male):0.6766(0.0024), Type of
fracture (lateral/G12):1.5154(0.0377), Type of surgery (os/
ap):1.8143(0.0083), Hospital type (university/
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capital):0.5784(0.0224), Surgical delay (12–24h/0–6h):
1.4374(0.0468), (24-h/0–6h):1.5077(0.0091), Co-morbidities
(yes/no):3.2845(0.0006), (II) with differentiating the co-
morbidities. Age: (70–79/60–69y):1.772(0.0117), (80–89/60–
69y):2.1756(0.0008), (90+/60–69y):4.8668(0), Type of surgery
(os/ap):1.7599(0.0198), Hospital type (university/
capital):0.4656(0.0032), Types of co-morbidities (ICD): C00-
C97:3.0667(0.0006), E10-E16:1.4339(0.0458), F00-
F99:2.0614(0.0003), I30-I52:4.2559(0), I70:1.5504(0.0013),
J00-J22:5.2241(0), L89:1.9277(0.0334). CONCLUSIONS:
Without differentiating co-morbidities, higher age, male gender,
lateral fracture, longer surgical delay, osteosynthesis surgery and
lower progressivity level of primary treatment proved to be of
higher risk for one year mortality. With the differentiation of
co-morbidities the role of surgical delay became weaker, while
certain co-morbidities had higher risk for one year mortality.
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OBJECTIVES: To explore the impact of the October 2004
withdrawal of rofecoxib on the use of surgical treatment for
osteoarthritis, speciﬁcally total hip and knee replacement.
METHODS: Patients were selected from the MarketScan data-
bases who, during January–September 2004, had a diagnosis of
osteoarthritis of the pelvis, thigh, or lower leg (ICD-9-CM
715.*5, 715.*6) on a medical claim and who ﬁlled prescrip-
tions for at least 90 days of therapy with rofecoxib, celecoxib
(an alternative COX-2 inhibitor that continued to be available),
or meloxicam (a patented, non-selective, nonsteroidal, anti-
inﬂammatory drug). For each cohort, the quarterly number of
total hip or knee replacement (THR/TKR) surgeries was
tracked before the withdrawal of rofecoxib (Q1-Q3 2004) and
subsequent to withdrawal (Q4 2004-Q4 2006). RESULTS: The
study cohorts included 31,551 rofecoxib users, 38,388 cele-
coxib users, and 7,007 meloxicam users. During the three quar-
ters prior to the withdrawal of rofecoxib the average quarterly
incidence of THR/TKR in these three cohorts was 2.2%, 1.9%,
and 2.0% respectively. Over the three quarters following the
Vioxx withdrawal, these rates increased to 2.8% for rofecoxib,
2.4% for celecoxib, and 2.6% for meloxicam, then in the next
three quarters decreased to 2.3%, 2.2%, and 2.3% respectively.
Rates of THR/TKR peaked in all groups in Q1 2005. The rate
of growth over Q1 2004 was 45% for rofecoxib, 38% for
celecoxib, and 71% for meloxicam. Quarterly rates of THR/
TKR then declined steadily and at the end of 2006 were similar
to the beginning of 2004. CONCLUSIONS: These results
suggest that the withdrawal of rofecoxib had the result of tem-
porarily increasing the use of THR/TKR to treat osteoarthritis.
This effect was seen not only among rofecoxib users, but also
patients receiving other drugs for whom a major non-surgical
treatment option was removed.
MUSCULAR-SKELETAL DISORDERS—Cost Studies
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OBJECTIVES: To evaluate the impact on Italian National
Health Service (NHS) budget of the introduction of Rituximab
(RTX) and Abatacept (ABAT) in the treatment of rheumatoid
arthritis (RA) patients not adequately responding to anti-TNFa
therapies. METHODS: First, RA patients eligible to second-line
biologic treatments and the available strategies for their man-
agement were identiﬁed and quantiﬁed; second, costs associated
to the different alternatives were estimated; ﬁnally, the impact
on the NHS budget was estimated using a cohort simulation
based on a Markov chain with 1-year cycles and a time horizon
of 10 years. Only direct medical costs were considered, includ-
ing drug acquisition, administration, incidental premedication
and monitoring tests and exams RESULTS: Italian RA patients
eligible to second-line biologic therapies were estimated in
about 1,300 per year. Three strategies were identiﬁed as avail-
able: the currently used strategy, based on the switch between
anti-TNFa therapies, and two innovative strategies based on
RTX and on ABAT. The simulated effect of a progressive
replacement (16%, 50%, and 100% at years 1, 5, and 10,
respectively) of the current strategy with the two new strategies
yielded the following results: RTX therapy induces a decrease
of costs of 1.16 million Euro (-7.1% with respect to current
strategy), 4.91 (-7.7%) and 4.94 (-5.3%) at years 1, 5, and 10,
whereas ABAT therapy induces an increase of 0.6 million Euro
(+3.7%), 5.43 (+8.5%) and 20.62 (22.2%). In the direct
comparison between the two new strategies RTX results less
expensive (10.4%, 14.9% and 22.5% at years 1, 5, and 10,
respectively). CONCLUSIONS: The introduction of new thera-
pies in the treatment of Italian RA patients represents a valu-
able option. The use of RTX is expected to induce a reduction
in costs while ABAT probably would produce an increase.
These results are preliminary, more detailed data on the popu-
lation and observed costs are needed.
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Leﬂunomide is recommended as an effective therapeutic option in
patients with methotrexate-resistant rheumatoid arthritis. Its use
in Poland is limited as it is available only in Therapeutic Pro-
gramme. OBJECTIVES: To assess the potential impact on the
Polish health care budget of introducing leﬂunomide reimburse-
ment in rheumatoid arthritis in Poland.METHODS:Analysis was
conducted from the perspective of National Health Fund. Only
direct medical costs including costs of leﬂunomide, DMARDs,
NSAIDs, steroids, outpatients and hospitalizations were consid-
ered. Data from Central Statistical Ofﬁce, Polish Ministry of
Health, National Health Fund, Institute of Rheumatology, IMS
and experts opinion were used. Current total budget spent on
treating rheumatoid patients was estimated. Three different sce-
narios of leﬂunomide use rate were proposed. Time horizon was 5
years. According to AHTAPol guidelines discounting was not
performed. Univariate sensitivity analysis was conducted.
RESULTS: Leﬂunomide reimbursement would impose additional
cost per year on the Polish health care service of PLN6.6 million
(€1.9 million) in the base case scenario. The corresponding range
was estimated at PLN3.0 (€0.9 million) and PLN 28.2 million
(€8.5 million) in the optimistic and pessimistic scenarios, respec-
tively (price level 2008). These costs represent 1.9 % and between
0.9% and 9.6% the total amount currently used on treating
patients with rheumatoid arthritis.CONCLUSIONS: Reimburse-
ment of leﬂunomide for patients with RA should pose a moderate
ﬁnancial burden on the Polish health care system.
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